sarilumab   Click here for help

GtoPdb Ligand ID: 7999

Synonyms: Kevzara® | REGN88 | SAR153191
Approved drug Immunopharmacology Ligand
sarilumab is an approved drug (EMA & FDA (2017))
Compound class: Antibody
Comment: Sarilumab is a monoclonal antibody directed against the interleukin 6 receptor (IL6R).
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. Peptide sequence BLAST search using the heavy and light chain variable regions of sarilumab provides 100% matches to sequences covered by patent US7582298 [4], and to the antibody with designation VQ8F11-21.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Immunopharmacology Comments
In clinical trial sarilumab significantly reduced the signs and symptoms of RA and improved physical function [1-2,5]. A notable side-effect is immune suppression leading to susceptibility to infection.
Immunopharmacology Disease
Disease X-Refs Comment References
Rheumatoid arthritis Disease Ontology: DOID:7148
OMIM: 180300
 FDA approved therapeutic for RA (May 2017).
Ankylosing spondylitis Disease Ontology: DOID:7147
 Clinical trial in ankylosing spondylitis was terminated.
Uveitis Disease Ontology: DOID:13141
 Completed Phase 2 clinical trial for non-infectious uveitis (see NCT01900431).